放射性<sup>125</sup>I粒子在肺腺癌EMT及临床治疗中的作用

宋飞; 车佳音; 黄明; 徐丹; 李红阳; 李定坤; 向盈盈

doi:10.12259/j.issn.2095-610X.S20230101

放射性¹²⁵I粒子在肺腺癌EMT及临床治疗中的作用

doi: 10.12259/j.issn.2095-610X.S20230101

1.
昆明医科大学第三附属医院/云南省肿瘤医院微创介入科
2.
屏边苗族自治县人民医院医学检验科，云南屏边　661200
3.
昆明医科大学第三附属医院/云南省肿瘤医院肝胆胰外科，云南昆明　650118
4.
昆明市延安医院口腔科，云南昆明　650051

基金项目: 国家自然科学基金资助项目（31860147）；昆明市卫生健康委员会卫生科研基金资助项目（2022-08-01-004）

详细信息

作者简介:
宋飞（1981～），男，云南昆明人，医学博士，副主任医师，主要从事肿瘤综合介入治疗临床工作

通讯作者:
向盈盈，E-mail： 198181981@qq.com

中图分类号: R734.2
计量
- 文章访问数: 3833
- HTML全文浏览量: 2231
- PDF下载量: 10
- 被引次数: 3
出版历程
- 收稿日期: 2022-10-14
- 刊出日期: 2023-01-25

The Role of Radioactive Iodine-125 Particles in EMT and Clinical Treatment of Lung Adenocarcinoma

1.
Dept. of Invasive Intervention，The 3rd Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital，Kunming Yunnan 650118
2.
Dept. of Medical Laboratory，Pingbian Miao Autonomous County People’s Hospital，Pingbian Yunnan，661200
3.
Dept. of Hepatobiliary and Pancreatic Surgery，The 3rd Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital，Kunming Yunnan 650118
4.
Dept. of Stomatology，Yan’an Hospital of Kunming City，Kunming Yunnan 650051，China

摘要

摘要: 肺癌是最常见的肿瘤之一，而云南省肺癌的发病率位居全国首位。许多患者确诊时已为晚期肺癌，采用多手段联合治疗，包括化学治疗、放射治疗、靶向治疗、免疫治疗以及局部治疗（消融、冷冻、¹²⁵I等）。放射性¹²⁵I粒子植入治疗作为晚期肺癌局部治疗手段之一，有其独特的优势，其放射半径小，特异性照射靶向病灶，而对周围正常组织损伤小，并且临床效果较好。研究表明上皮-间质样表型转化（epithelial-mesenchymal transformation，EMT）与肺腺癌的生长、侵袭、转移密切相关。对放射性¹²⁵I粒子在肺腺癌EMT及临床治疗中的作用进行论述。
- 肺腺癌 /
- 上皮间质转化 /
- 放射性¹²⁵I粒子
Abstract: Lung cancer is one of the most common tumors, and Yunnan has the highest incidence of lung cancer in China. Many patients are diagnosed with advanced lung cancer and are treated with a combination of chemotherapy, radiotherapy, targeted therapy, immunotherapy, and local therapy （ablation, freezing, ¹²⁵I, etc.）. As one of the local treatment methods for advanced lung cancer, radioactive ¹²⁵I seed implantation has its unique advantages, such as small radiation radius, specific irradiation targeting of the lesion, and little damage to surrounding normal tissue, and good clinical effect. Studies have shown that epithelial mesenchymaltransformation （EMT） with lung adenocarcinoma is closely related to the growth, invasion, and metastasis. This article discusses the role of radioactive ¹²⁵I particles in EMT and clinical treatment of lung adenocarcinoma
- Lung adenocarcinoma /
- Epithelial-mesenchymal transformation /
- Radioactive iodine-125 particles

HTML全文

参考文献(21)

[1]	路友华,王炳翔,王家林,等. 中国居民1990-2019年肺癌及其危险因素疾病负担变化趋势分析[J]. 中国公共卫生,2022,38(5):513-517.
[2]	Zhuang H,Shi S,Guo Y,et al. Increase of secondary mutations may be a drug-resistance mechanism for lung adenocarcinoma after radiation therapy combined with tyrosine kinase inhibitor[J]. J Cancer,2019,10(22):5371-5376. doi: 10.7150/jca.35247
[3]	Tian X,Gu T,Lee M H,et al. Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer[J]. Biochim Biophys Acta Rev Cancer,2022,1877(1):188645. doi: 10.1016/j.bbcan.2021.188645
[4]	Wu F,Ji A,Zhang Z,et al. miR-491-5p inhibits the proliferation and migration of A549 cells by FOXP4[J]. Exp Ther Med,2021,21(6):622. doi: 10.3892/etm.2021.10054
[5]	Song J,Fan X,Zhao Z,et al. (125)I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy:A comparison with best supportive care[J]. Onco Targets Ther,2017,10(3):1345-1352.
[6]	Tang B,Xi Y,Cui F,et al. Ionizing radiation induces epithelial-mesenchymal transition in human bronchial epithelial cells[J]. Biosci Rep,2020,40(8):BSR20200453. doi: 10.1042/BSR20200453
[7]	Uribe M L,Marrocco I,Yarden Y. EGFR in Cancer: Signaling mechanisms, drugs, and acquired resistance[J]. Cancers (Basel),2021,13(11):2748. doi: 10.3390/cancers13112748
[8]	Matsubara T,Tagawa T,Takada K,et al. Clinical and prognostic significance of the epithelial-mesenchymal transition in stage IA lung adenocarcinoma:A propensity score-matched analysis[J]. Clin Lung Cancer,2019,20(4):e504-e513. doi: 10.1016/j.cllc.2019.04.006
[9]	Yu J J,Zhou D D,Yang X X,et al. TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target[J]. Nat Commun,2020,11(1):3660. doi: 10.1038/s41467-020-17385-0
[10]	Thompson J C,Hwang W T,Davis C,et al. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy[J]. Lung Cancer,2020,139(10):1-8.
[11]	刘登尧,叶尔麦克·阿哈提,李建邦. 放射性125碘粒子对肺腺癌A549细胞荷瘤裸鼠HIF-1α表达的影响[J]. 新疆医科大学学报,2021,44(2):133-136.
[12]	He Y,Li L,Liu J,et al. Iodine-125 seed brachytherapy inhibits non-small cell lung cancer by suppressing epithelial-mesenchymal transition[J]. Brachytherapy,2018,17(4):696-701. doi: 10.1016/j.brachy.2018.03.002
[13]	Sui A,Song H,Yu H,et al. Clinical application of iodine-125 seed brachytherapy combined with anti-PD-1 antibodies in the treatment of lung cancer[J]. Clin Ther,2020,42(8):1612-1616. doi: 10.1016/j.clinthera.2020.05.018
[14]	Chen C,Wang W,Yu Z,et al. Combination of computed tomography-guided iodine-125 brachytherapy and bronchial arterial chemoembolization for locally advanced stage III non-small cell lung cancer after failure of concurrent chemoradiotherapy[J]. Lung Cancer,2020,146(6):290-296.
[15]	吴春蓉,李波,向德兵,等. 碘-125粒子植入近距离放疗联合化疗治疗老年晚期非小细胞肺癌的临床研究[J]. 广西医学,2020,42(19):2487-2491.
[16]	姚雪原,郭彦伟,张红巧,等. CT引导下~(125)I粒子植入联合化疗治疗中晚期非小细胞肺癌的疗效及安全性研究[J]. 微创医学,2022,17(4):441-444.
[17]	田冲. 放射性碘125粒子植入联合全身化疗治疗晚期肺癌患者近远期疗效观察[J]. 医学理论与实践,2021,34(6):907-909.
[18]	Hong J,Shi Y B,Fu Y F,et al. Iodine-125 seeds insertion with trans-arterial chemical infusion for advanced lung cancer:a meta-analysis[J]. J Contemp Brachytherapy,2022,14(4):403-410.
[19]	张忠亮,肖越勇,张肖,等. ~(125)I粒子植入术联合支气管动脉化疗栓塞治疗纵隔型肺癌和/或肿瘤纵隔淋巴结转移[J]. 中国介入影像与治学,2022,19(12):756-760.
[20]	Ji Z ,Jiang Y ,Guo F ,et al. Safety and efficacy of CT-guided radioactive iodine-125 seed implantation assisted by a 3D printing template for the treatment of thoracic malignancies[J]. J Cancer Res Clin Oncol,2020,146(1):229-236. doi: 10.1007/s00432-019-03050-7
[21]	何禹. 碘-125粒子组织间植入联合支气管动脉灌注化疗治疗肺癌的疗效观察[J]. 医学食疗与健康,2022,20(15):43-45.

相关文章(20)

[1]	楼海均, 张振宇, 苏热彦·阿力木江, 孟·孟根, 陈航, 乌都木丽. TMEM33在肺腺癌的表达特征及临床病理特征, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20250304
[2]	杨晟强, 王平. Hsp90抑制剂Ganetespib联合培美曲塞对肺腺癌细胞的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240705
[3]	杨红秀, 朱中山. 肺腺癌中HPRT1基因表达对患者总生存的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240803
[4]	沈旺寻, 杨银煜, 李灿伟, 杨金荣, 伍思婧, 赵华君, 陀晓宇. ROR1在不同组织学分级浸润性肺腺癌中的表达与临床意义, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240509
[5]	徐冬杏, 唐波, 朱国, 雷学芬, 王秋虹, 魏东. Twist1调控Bmi1对胆囊癌细胞侵袭迁移的影响及其机制研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230320
[6]	马诗淇, 丁毅, 李敏, 王梦慈, 张思宇, 冯树梅. LINC00341通过MAPK通路抑制肺腺癌细胞增殖, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230403
[7]	刘邦卿, 李剑锋, 刘晓辉, 张劲男, 梁金屏. miR-196b靶向ERG促进肺腺癌的增殖和迁移, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231023
[8]	邹垚, 王梓瑜, 李皎, 李兴欣, 申亚琼, 徐敬, 金焰. LOXL2及Snail蛋白表达水平与胆管癌患者术后生存率的关系, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20221215
[9]	吴茂芳, 周永春, 蔡静静, 莫欣, 李瑛玮, 毛佳惠. 云南地区多结节肺腺癌EGFR突变及其临床意义, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220215
[10]	朱中山, 杨洲, 江承川, 李小兵, 任斗, 黄橙, 张维薇, 李湘军, 赵顺利. 肺腺癌患者PLA2G1B表达情况与预后的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220912
[11]	赵华君, 潘国庆, 唐莹, 王智园, 赵晓玮, 陀晓宇. ROR1在肺腺癌组织中的表达与气腔播散相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20221128
[12]	王应霞, 何琴, 王国芳, 张旋. 非小细胞肺癌中microRNA-21和EGFR的表达及意义, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210818
[13]	徐爱萍, 林华, 高丽辉, 李玲, 陈梦威, 王歌, 杨娟, 牛艳芬. 芒果苷元对TGF-β1诱导的HK-2细胞EMT的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210701
[14]	段宏民, 陈楠, 杨永燕, 李云霞, 冯金象, 李航, 黄秀文, 吕东津, 张明, 赵玉涛. 安罗替尼对肺腺癌细胞株A549放射敏感性的影响及机制, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210808
[15]	马燕粉, 胡建, 张宁, 武倩, 王晓琴. 肺腺癌性与结核性胸腔积液患者凝血指标变化及异常模式, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20211021
[16]	吴琪燕, 边革元, 程绘珺, 李娇霞, 王书廷, 黄照略. 肺腺癌预后因素及血清肿瘤标记物的诊断效能, 昆明医科大学学报.
[17]	朱中山, 严文辉, 李小兵, 杨洲, 白鹏. 200例肺腺癌脑转移患者驱动基因突变情况及预后关系, 昆明医科大学学报.
[18]	赵斌, 李瑞乾, 张国颖, 雷永虹, 王启林, 刘志敏. 过表达miR-4328抑制前列腺癌细胞的增殖、迁移和上皮间质转化, 昆明医科大学学报.
[19]	王华. 吉非替尼治疗晚期肺腺癌临床观察, 昆明医科大学学报.
[20]	. 肺腺癌A549细胞中Nestin的表达, 昆明医科大学学报.

施引文献

期刊类型引用(3)

1.	伦冰，岳少婷，樊少磊，阮海慧，荆冬冬. 非自愿终止妊娠女性心理体验质性研究的Meta整合. 护士进修杂志. 2024(07): 737-743 . 百度学术
2.	朱楚玲，林丽卿，林英英. 2018—2022年福建省泉州市围产儿死亡影响因素分析. 中国妇幼卫生杂志. 2024(04): 11-15 . 百度学术
3.	许瑾瑾，刘圣英，陈燕玲. 70例妊娠晚期死胎死因及相关影响因素分析. 中国实用医药. 2024(20): 63-67 . 百度学术